These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38358037)

  • 21. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
    Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A
    Front Immunol; 2021; 12():708939. PubMed ID: 34456918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
    Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH
    J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants.
    Clegg L; Freshwater E; Leach A; Villafana T; Hamrén UW
    J Clin Pharmacol; 2024 May; 64(5):555-567. PubMed ID: 38294353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.
    Blake SM; Tanaka D; Bendz LM; Staebler S; Brandon D
    Adv Neonatal Care; 2017 Aug; 17(4):292-298. PubMed ID: 27926583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic.
    Tam DY; Banerji A; Paes BA; Hui C; Tarride JE; Lanctôt KL
    J Med Econ; 2009; 12(4):361-70. PubMed ID: 19900071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
    Nuijten MJ; Wittenberg W; Lebmeier M
    Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
    Domachowske J; Madhi SA; Simões EAF; Atanasova V; Cabañas F; Furuno K; Garcia-Garcia ML; Grantina I; Nguyen KA; Brooks D; Chang Y; Leach A; Takas T; Yuan Y; Griffin MP; Mankad VS; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):892-894. PubMed ID: 35235733
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.
    McGirr AA; Schwartz KL; Allen U; Solomon M; Sander B
    Hum Vaccin Immunother; 2017 Mar; 13(3):599-606. PubMed ID: 27768505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.